17 Articles in October 2026
FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know
Overview of the Regulatory Action According to a client alert from the law firm Buchanan Ingersoll & Rooney PC, the U.S.
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
Pharmacists Must Guide Peptide Talks Pending FDA Action, NCPA 2026 Session Signals Pharmacists are being urged to take a proactive role in counseling patients on peptide therapies even as the Food and Drug Administration continues to weigh how it will regulate this fast-growing category of compound...
Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients
Houston Compounding Pharmacy Faces Scrutiny After FDA Finds 14 Violations Tied to Recalled Tirzepatide Vials A Houston-based compounding pharmacy linked to a recall of compounded tirzepatide injectable vials was cited by the U.S.
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
Apothecary Pharma Recalls Compounded Tirzepatide and NAD+ Vials Over Sterility Concerns Apothecary Pharma has issued a recall of compounded tirzepatide and NAD+ (nicotinamide adenine dinucleotide) injectable vials due to sterility concerns, according to a report from Managed Healthcare Executive.
North Carolina Compounder Recalls Tirzepatide Vials…
North Carolina Compounder Recalls Tirzepatide Vials Amid Ongoing Scrutiny of Compounded GLP-1 Products A compounding pharmacy based in North Carolina has issued a recall of tirzepatide vials, according to a report circulated via Google News and aggregated by inkl.
Twenty AGs Issue Letter on Chinese-Sourced Ingredients in Some Compounded GLP-1s and Peptides
Twenty State Attorneys General Raise Alarms Over Chinese-Sourced Ingredients in Compounded GLP-1 Drugs A coalition of twenty state attorneys general has issued a letter addressing concerns about Chinese-sourced active pharmaceutical ingredients (APIs) used in some compounded versions of GLP-1 recep...
US FDA takes step to change peptide compounding policy
Overview of the Regulatory Action Reuters has reported that the U.S. Food and Drug Administration is moving to revise its policy governing the compounding of peptide drugs, a category of therapeutics that has exploded in popularity and regulatory scrutiny over the past several years.
FDA Peptide Compounding Policy: What a Temporary Enforcement Reprieve Could Mean for Pharmacies
Overview of the Regulatory Action The compounding pharmacy industry received notable, if temporary, relief in a recent regulatory development concerning peptide products, as reported by law firm Buchanan Ingersoll & Rooney PC. According to the firm's analysis, the U.S.
fda approved peptide drugs for weight loss 2026
FDA's Peptide Weight-Loss Pipeline Faces Scrutiny as 2026 Approvals Loom Regulatory attention on peptide-based weight-loss drugs is intensifying as the pharmaceutical industry anticipates a new wave of potential FDA approvals in 2026.
FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles
FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles The U.S.
Eli Lilly’s Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know
Eli Lilly's Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know Eli Lilly and Company has expanded its legal campaign against unauthorized sales of its investigational weight-loss and metabolic drug retatrutide, filing lawsuits that legal analysts say cou...
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
Pharmacy Law Lowdown: FDA's Evaluation of Peptides The U.S. Food and Drug Administration's ongoing scrutiny of peptide products is once again in the spotlight, following a report published by Drug Topics under its "Pharmacy Law Lowdown" series examining the agency's evaluation of peptides.
The FDA Is Struggling To Police The Peptide Boom
The FDA Is Struggling To Police The Peptide Boom The Food and Drug Administration is facing mounting difficulty controlling the rapid proliferation of therapeutic and performance-enhancing peptides flooding the American marketplace, according to a Forbes report examining the agency's regulatory gap...
FDA warns about some peptide injections possibly linked to illnesses
FDA Warns About Some Peptide Injections Possibly Linked to Illnesses The U.S. Food and Drug Administration has issued a warning regarding certain peptide injections that may be associated with reported illnesses, according to a report from NBC News.
Henry Meds Lawsuit (Updated September 2026)
Henry Meds Faces Continued Legal Scrutiny Amid Broader Compounded Peptide Crackdown Henry Meds, one of the more prominent telehealth platforms selling compounded GLP-1 medications such as semaglutide and tirzepatide, remains the subject of ongoing litigation tracking, according to an updated report...
FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies
FDA Warning Letter to Empower Pharmacy Signals Heightened Scrutiny of 503A Compounders The U.S. Food and Drug Administration has issued a warning letter to Empower Pharmacy, one of the nation's largest compounding pharmacies, according to reporting from the law firm Buchanan Ingersoll & Rooney PC.
FDA Recalls and Warnings: Glutathione Peptide Injections Recalled Over Endotoxin Contamination
FDA Recalls and Warnings: Glutathione Peptide Injections Recalled Over Endotoxin Contamination Federal regulators have flagged injectable glutathione products for endotoxin contamination, according to a report from MedShadow.